Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 1/20 | 0.37 |
| ▸ | ADSS2 | P30520 | 1/20 | 0.31 |
| ▸ | TK1 | P04183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946191 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL15071493 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL14928703 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL15249232 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL17263511 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL20126561 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL15248821 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL14946187 | 0.90 | P2RY2 (0.37) | RNASEL | |
| SCHEMBL15071506 | 0.81 | PGD (0.31) | TK1 | |
| SCHEMBL15248823 | 0.81 | PGD (0.31) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2018-01-04 | — | — | US | disclosed |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-28 | — | — | US | disclosed |
| US-9828416-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9782462-B2 | Modified polynucleotides for the production of proteins associated with human disease | MODERNATX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160375134-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-12-29 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20140378538-A1 | METHODS OF RESPONDING TO A BIOTHREAT | MODERNATX, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140193482-A1 | MODIFIED POLYNUCLEOTIDES ENCODING V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG | MODERNA THERAPEUTICS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140186432-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CITED4 | MODERNA THERAPEUTICS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140179771-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING DOLICHYL-PHOSPHATE (UDP-N-ACETYLGLUCOSAMINE) N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE 1 (GLCNAC-1-P TRANSFERASE) PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140155475-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING LIPASE A, LYSOSOMAL ACID, CHOLESTEROL ESTERASE PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155474-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING CYSTIC FIBROSIS | MODERNA THERAPEUTICS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140107189-A1 | MODIFIED POLYNUCLEOTIDES ENCODING APOPTOSIS INDUCING FACTOR 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | RNASEL 61/4885ADSS2 317/4885TK1 198/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | RNASEL 34/4885ADSS2 526/4885TK1 339/4885 |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | RNASEL 361/4885ADSS2 3293/4885TK1 616/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | RNASEL 35/4885ADSS2 400/4885TK1 535/4885 |
| US-20140186432-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CITED4 | POLN, CXXC4, POLRMT | RNASEL 1074/4885ADSS2 4090/4885TK1 840/4885 |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | POLRMT, POLN, PHAX | RNASEL 614/4885ADSS2 3916/4885TK1 400/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | RNASEL 35/4885ADSS2 400/4885TK1 535/4885 |
| US-20160375134-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | MSH2, POLRMT, SARNP | RNASEL 145/4885ADSS2 3002/4885TK1 807/4885 |
| US-20140179771-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING DOLICHYL-PHOSPHATE (UDP-N-ACETYLGLUCOSAMINE) N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE 1 (GLCNAC-1-P TRANSFERASE) PROTEIN DEFICIENCY | POLRMT, POLN, GALNT1 | RNASEL 260/4885ADSS2 1472/4885TK1 166/4885 |
| US-20140155474-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING CYSTIC FIBROSIS | POLRMT, CFTR, POLN | RNASEL 109/4885ADSS2 3381/4885TK1 615/4885 |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | TIA1, PAIP1, PHAX | RNASEL 317/4885ADSS2 1904/4885TK1 1193/4885 |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | NSUN3, PLIN3, MCOLN3 | RNASEL 2331/4885ADSS2 3282/4885TK1 2236/4885 |
| US-20140193482-A1 | MODIFIED POLYNUCLEOTIDES ENCODING V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG | MYC, MYCBP, POLN | RNASEL 380/4885ADSS2 3855/4885TK1 522/4885 |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | RNASEL 142/4885ADSS2 2348/4885TK1 833/4885 |
| US-20140107189-A1 | MODIFIED POLYNUCLEOTIDES ENCODING APOPTOSIS INDUCING FACTOR 1 | MSH2, APAF1, MCL1 | RNASEL 455/4885ADSS2 3915/4885TK1 493/4885 |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | MSH2, POLN, MSH6 | RNASEL 302/4885ADSS2 3891/4885TK1 634/4885 |
| US-20140378538-A1 | METHODS OF RESPONDING TO A BIOTHREAT | POLRMT, RNMT, RNGTT | RNASEL 24/4885ADSS2 805/4885TK1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.